
Safety & quality
Adverse event
Also found as: adverse events · AE · AEs · treatment-emergent adverse events
An unfavorable medical occurrence recorded during a study, with causation assessed separately. The eye trial tabulates events and their relationship to study treatment.[1]
Source check: 2026-10-04 · Editorial method
How the research uses this term
The report distinguishes ocular from non-ocular events and summarizes events in both treatment and placebo groups. It also records severity, seriousness and treatment relationship.[1]
Reading the evidence
An event count and a count of affected participants are different quantities. The trial reports both, along with separate assessments of whether events were related to treatment.[1]
Used in our guides
Continue reading where this term appears.
- TirzepatideRead the term in context
- RetatrutideRead the term in context
- TesamorelinRead the term in context
- MOTS-cRead the term in context
- SermorelinRead the term in context
- PT-141 / bremelanotideRead the term in context
- CagrilintideRead the term in context
- SS-31 / elamipretideRead the term in context
- KPVRead the term in context
- SemaxRead the term in context
- SelankRead the term in context
- Epitalon / EpithalonRead the term in context
- Thymosin alpha-1Read the term in context
- AOD-9604Read the term in context
- Melanotan IIRead the term in context
- DSIPRead the term in context
- IGF-1 LR3Read the term in context
- GHRP-2Read the term in context
- GHRP-6Read the term in context
- Kisspeptin-10Read the term in context
- OxytocinRead the term in context
- LL-37Read the term in context
- HexarelinRead the term in context
- CJC-1295 + ipamorelinRead the term in context
- Tesamorelin + ipamorelinRead the term in context
- Semax + SelankRead the term in context
- Sermorelin + ipamorelinRead the term in context
- Retatrutide + cagrilintideRead the term in context
- MOTS-c + SS-31Read the term in context
- BPC-157 + KPVRead the term in context
- Tesamorelin + CJC-1295 + ipamorelinRead the term in context
- Tirzepatide + cagrilintideRead the term in context
- Tesamorelin + AOD-9604Read the term in context
- Tesamorelin + MOTS-cRead the term in context
- AOD-9604 + MOTS-cRead the term in context
- MOTS-c + NAD+Read the term in context
- MOTS-c + SS-31 + NAD+Read the term in context
- BPC-157 + TB-500 + KPVRead the term in context
- BPC-157 + TB-500 + CJC-1295 + ipamorelinRead the term in context
- CJC-1295 + ipamorelin + GHK-CuRead the term in context
- GHK-Cu + EpitalonRead the term in context
- Epitalon + thymalinRead the term in context
- DSIP + ipamorelinRead the term in context
- PT-141 + oxytocinRead the term in context
- Tirzepatide + tesamorelinRead the term in context
- Retatrutide + MOTS-cRead the term in context
- Retatrutide + tirzepatideRead the term in context
- Semaglutide + B12Read the term in context
- Tirzepatide + B12Read the term in context
References
Definitions and explanations are paraphrased. The source locations below identify the supporting passages and methods.
- 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical TrialPrimary research · Human randomized trial · 2023DOI: 10.3390/ijms24010554
Source locations: Safety results; Tables 5–6; Tables 5–6.
Review status · PendingSource packet file
0_1_RGN_259_Thymosin_4_Ophthalmic_Solution_Promotes_Healing_and_Improves_36613994_PMC9820614.pdf